{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:52:03Z","timestamp":1795110723944,"version":"4.10.3"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To synthesize the current preclinical and clinical evidence on the utility and potential mechanisms of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a therapeutic strategy for major ophthalmic diseases, including diabetic retinopathy, glaucoma, and age-related macular degeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted to synthesize the current preclinical and clinical evidence. Electronic databases including PubMed, Embase, and Web of Science were searched from inception until August 2025 using keywords such as \u201cGLP-1 receptor agonist,\u201d \u201cdiabetic retinopathy,\u201d \u201cglaucoma,\u201d \u201cage-related macular degeneration,\u201d \u201cocular disease,\u201d and \u201cneuroprotection.\u201d The search focused on identifying preclinical studies, large-scale retrospective cohort studies, and post-hoc analyses of major clinical trials that evaluated the utility and potential mechanisms of GLP-1RAs in ophthalmic diseases. Studies were screened for relevance based on title and abstract, and full texts were retrieved for detailed assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Despite heterogeneity in study designs and populations, a largely consistent association was found between GLP-1RA use and a reduced incidence of glaucoma. For diabetic retinopathy, the evidence was nuanced, indicating potential long-term neurovascular protection but also a risk of transient early worsening. For age-related macular degeneration, findings were dichotomous, suggesting a protective effect against non-exudative forms but a potential increased risk for neovascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1RAs show significant promise as a potential disease-modifying therapy for neurodegenerative and inflammatory eye diseases, acting through both systemic metabolic improvements and direct ocular mechanisms, representing a paradigm shift beyond their metabolic indications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-025-04559-x","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:04:30Z","timestamp":1767837870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["GLP-1 receptor agonists in eye disease: a comprehensive review of current research and future potential"],"prefix":"10.1186","volume":"26","author":[{"given":"Yu","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"4","key":"4559_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001.","journal-title":"Cell Metab"},{"issue":"11\u201312","key":"4559_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1055\/s-2004-826160","volume":"36","author":"CF Deacon","year":"2004","unstructured":"Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004;36(11\u201312):761\u201365. https:\/\/doi.org\/10.1055\/s-2004-826160.","journal-title":"Horm Metab Res"},{"issue":"3 Pt 1","key":"4559_CR3","doi-asserted-by":"publisher","first-page":"E458","DOI":"10.1152\/ajpendo.1996.271.3.E458","volume":"271","author":"CF Deacon","year":"1996","unstructured":"Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol. 1996;271(3 Pt 1):E458\u201364. https:\/\/doi.org\/10.1152\/ajpendo.1996.271.3.E458.","journal-title":"Am J Physiol"},{"issue":"11","key":"4559_CR4","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1124\/dmd.110.034066","volume":"38","author":"M Malm-Erjef\u00e4lt","year":"2010","unstructured":"Malm-Erjef\u00e4lt M, Bj\u00f8rnsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010;38(11):1944\u201353. https:\/\/doi.org\/10.1124\/dmd.110.034066.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"4559_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s13300-023-01381-w","volume":"14","author":"K Heinla","year":"2023","unstructured":"Heinla K, Vasar E, Reppo I, Sedman T, Volke V. GLP-1 receptor agonists induce growth hormone secretion in healthy volunteers. Diabetes Ther. 2023;14(4):777\u201386. https:\/\/doi.org\/10.1007\/s13300-023-01381-w.","journal-title":"Diabetes Ther"},{"key":"4559_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fendo.2020.00178","volume":"11","author":"MP Gilbert","year":"2020","unstructured":"Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol (Lausanne). 2020;11:178. Published 2020 Apr 3. https:\/\/doi.org\/10.3389\/fendo.2020.00178.","journal-title":"Front Endocrinol (lausanne)"},{"issue":"Suppl 1","key":"4559_CR7","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140\u201357. https:\/\/doi.org\/10.2337\/dc23-S009.","journal-title":"Diabetes Care"},{"issue":"6","key":"4559_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819\u201337. https:\/\/doi.org\/10.1016\/j.cmet.2013.04.008.","journal-title":"Cell Metab"},{"issue":"11","key":"4559_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"1","key":"4559_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892.","journal-title":"N Engl J Med"},{"issue":"10","key":"4559_CR11","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","volume":"125","author":"TY Wong","year":"2018","unstructured":"Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye Care: the International council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125(10):1608\u201322. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.007.","journal-title":"Ophthalmology"},{"issue":"10414","key":"4559_CR12","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(23)01289-8","volume":"402","author":"H Jayaram","year":"2023","unstructured":"Jayaram H, Kolko M, Friedman DS, Gazzard G. Glaucoma: now and beyond. Lancet. 2023;402(10414):1788\u2013801. https:\/\/doi.org\/10.1016\/S0140-6736(23)01289-8.","journal-title":"Lancet"},{"issue":"3","key":"4559_CR13","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3390\/ijms22031296","volume":"22","author":"Y Ruan","year":"2021","unstructured":"Ruan Y, Jiang S, Gericke A. Age-related macular degeneration: role of oxidative stress and blood vessels. Int J Mol Sci. 2021;22(3):1296. Published 2021 Jan 28. https:\/\/doi.org\/10.3390\/ijms22031296.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4559_CR14","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","volume":"136","author":"FG Holz","year":"2018","unstructured":"Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of Lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 2018;136(6):666\u201377. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.1544.","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"4559_CR15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/anae.16306","volume":"79","author":"DA Milder","year":"2024","unstructured":"Milder DA, Milder TY, Liang SS, Kam PCA. Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice [published correction appears in anaesthesia. 2024 Oct; 79(10): 1138. doi: 10.1111\/anae.16427]. Anaesthesia. 2024;79(7):735\u201347. https:\/\/doi.org\/10.1111\/anae.16306.","journal-title":"Anaesthesia"},{"issue":"12","key":"4559_CR16","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728\u201342. https:\/\/doi.org\/10.1038\/nrendo.2012.140.","journal-title":"Nat Rev Endocrinol"},{"issue":"10278","key":"4559_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0.","journal-title":"Lancet"},{"key":"4559_CR18","doi-asserted-by":"publisher","first-page":"109647","DOI":"10.1016\/j.intimp.2022.109647","volume":"115","author":"MA Sadek","year":"2023","unstructured":"Sadek MA, Kandil EA, El Sayed NS, Sayed HM, Rabie MA. Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: involvement of the PI3K\/Akt\/GSK-3\u03b2 pathway. Int Immunopharmacol. 2023;115:109647. https:\/\/doi.org\/10.1016\/j.intimp.2022.109647.","journal-title":"Int Immunopharmacol"},{"issue":"Pt 3","key":"4559_CR19","doi-asserted-by":"publisher","first-page":"113537","DOI":"10.1016\/j.intimp.2024.113537","volume":"143","author":"N Siddeeque","year":"2024","unstructured":"Siddeeque N, Hussein MH, Abdelmaksoud A, et al. Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: a large-scale propensity-matched cohort study. Int Immunopharmacol. 2024;143(Pt 3):113537. https:\/\/doi.org\/10.1016\/j.intimp.2024.113537.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4559_CR20","doi-asserted-by":"publisher","first-page":"e3070","DOI":"10.1002\/dmrr.3070","volume":"35","author":"R Gentilella","year":"2019","unstructured":"Gentilella R, Pechtner V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Diabetes Metab Res Rev. 2019;35(1):e3070. https:\/\/doi.org\/10.1002\/dmrr.3070.","journal-title":"Diabetes Metab Res Rev"},{"key":"4559_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2202-13-33","volume":"13","author":"K Hunter","year":"2012","unstructured":"Hunter K, H\u00f6lscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33. Published 2012 Mar 23. https:\/\/doi.org\/10.1186\/1471-2202-13-33.","journal-title":"BMC Neurosci"},{"issue":"3","key":"4559_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","volume":"27","author":"AJ Kastin","year":"2003","unstructured":"Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord. 2003;27(3):313\u201318. https:\/\/doi.org\/10.1038\/sj.ijo.0802206.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"4559_CR23","unstructured":"Novo Nordisk A\/S. Victoza (liraglutide) prescribing information. Updated 25 August 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022341s027lbl.pdf. Accessed October 25 2017."},{"key":"4559_CR24","unstructured":"Novo Nordisk A\/S. Ozempic (semaglutide) prescribing information. Dated December 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf. Accessed July 9 2018."},{"key":"4559_CR25","unstructured":"Eli Lilly and Company. Trulicity (dulaglutide) prescribing information. Updated 1 August 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125469s011s013lbl.pdf. Accessed May 1 2018."},{"issue":"1","key":"4559_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2019Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169. Published 2022 Sep 1. https:\/\/doi.org\/10.1186\/s12933-022-01604-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"13","key":"4559_CR27","doi-asserted-by":"publisher","first-page":"e2116506119","DOI":"10.1073\/pnas.2116506119","volume":"119","author":"B Sun","year":"2022","unstructured":"Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci USA. 2022;119(13):e2116506119. https:\/\/doi.org\/10.1073\/pnas.2116506119.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"4559_CR28","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","volume":"82","author":"YY Syed","year":"2022","unstructured":"Syed YY. Tirzepatide: first approval. Drugs. 2022;82(11):1213\u201320. https:\/\/doi.org\/10.1007\/s40265-022-01746-8.","journal-title":"Drugs"},{"issue":"10103","key":"4559_CR29","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4.","journal-title":"Lancet"},{"issue":"13","key":"4559_CR30","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C, et al. Trial of Lixisenatide in early Parkinson\u2019s disease. N Engl J Med. 2024;390(13):1176\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2312323.","journal-title":"N Engl J Med"},{"issue":"1","key":"4559_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024;23(1):37\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(23)00378-2.","journal-title":"Lancet Neurol"},{"key":"4559_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bbr.2018.08.006","volume":"356","author":"KT Watson","year":"2019","unstructured":"Watson KT, Wroolie TE, Tong G, et al. Neural correlates of liraglutide effects in persons at risk for Alzheimer\u2019s disease. Behav Brain Res. 2019;356:271\u201378. https:\/\/doi.org\/10.1016\/j.bbr.2018.08.006.","journal-title":"Behav Brain Res"},{"key":"4559_CR33","doi-asserted-by":"publisher","unstructured":"Salameh TS, Rhea EM, Talbot K, Banks WA. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics [published correction appears in biochem pharmacol. 2023 Apr; 210: 115474. doi: https:\/\/doi.org\/10.1016\/j.Bcp.2023.115474. Biochem Pharmacol. 2020;180:114187.","DOI":"10.1016\/j.Bcp.2023.115474"},{"issue":"9","key":"4559_CR34","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1517\/17425255.2013.796928","volume":"9","author":"J Jord\u00e1n","year":"2013","unstructured":"Jord\u00e1n J, Ru\u00edz-Moreno JM. Advances in the understanding of retinal drug disposition and the role of blood-ocular barrier transporters. Expert Opin Drug Metab Toxicol. 2013;9(9):1181\u201392. https:\/\/doi.org\/10.1517\/17425255.2013.796928.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"4559_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1124\/pr.55.1.6","volume":"55","author":"KE Mayo","year":"2003","unstructured":"Mayo KE, Miller LJ, Bataille D, et al. International Union of pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003;55(1):167\u201394. https:\/\/doi.org\/10.1124\/pr.55.1.6.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"4559_CR36","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2337\/db15-0443","volume":"65","author":"C Hern\u00e1ndez","year":"2016","unstructured":"Hern\u00e1ndez C, Bogdanov P, Corraliza L, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes. 2016;65(1):172\u201387. https:\/\/doi.org\/10.2337\/db15-0443.","journal-title":"Diabetes"},{"issue":"9","key":"4559_CR37","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1111\/dom.13339","volume":"20","author":"JB Hebsgaard","year":"2018","unstructured":"Hebsgaard JB, Pyke C, Yildirim E, Knudsen LB, Heegaard S, Kvist PH. Glucagon-like peptide-1 receptor expression in the human eye. Diabetes Obes Metab. 2018;20(9):2304\u201308. https:\/\/doi.org\/10.1111\/dom.13339.","journal-title":"Diabetes Obes Metab"},{"key":"4559_CR38","doi-asserted-by":"publisher","first-page":"101219","DOI":"10.1016\/j.mam.2023.101219","volume":"94","author":"J Lo","year":"2023","unstructured":"Lo J, Mehta K, Dhillon A, et al. Therapeutic strategies for glaucoma and optic neuropathies. Mol Aspects Med. 2023;94:101219. https:\/\/doi.org\/10.1016\/j.mam.2023.101219.","journal-title":"Mol Aspects Med"},{"key":"4559_CR39","doi-asserted-by":"publisher","first-page":"106516","DOI":"10.1016\/j.phrs.2022.106516","volume":"185","author":"R Amato","year":"2022","unstructured":"Amato R, Catalani E, Dal Monte M, Cammalleri M, Cervia D, Casini G. Morpho-functional analysis of the early changes induced in retinal ganglion cells by the onset of diabetic retinopathy: the effects of a neuroprotective strategy. Pharmacol Res. 2022;185:106516. https:\/\/doi.org\/10.1016\/j.phrs.2022.106516.","journal-title":"Pharmacol Res"},{"key":"4559_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","volume":"303","author":"W Liu","year":"2015","unstructured":"Liu W, Jalewa J, Sharma M, Li G, Li L, H\u00f6lscher C. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson\u2019s disease. Neuroscience. 2015;303:42\u201350. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.06.054.","journal-title":"Neuroscience"},{"issue":"7","key":"4559_CR41","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kam TI, Panicker N, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease. Nat Med. 2018;24(7):931\u201338. https:\/\/doi.org\/10.1038\/s41591-018-0051-5.","journal-title":"Nat Med"},{"issue":"5","key":"4559_CR42","doi-asserted-by":"publisher","first-page":"108271","DOI":"10.1016\/j.celrep.2020.108271","volume":"33","author":"JK Sterling","year":"2020","unstructured":"Sterling JK, Adetunji MO, Guttha S, et al. GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension. Cell Rep. 2020;33(5):108271. https:\/\/doi.org\/10.1016\/j.celrep.2020.108271.","journal-title":"Cell Rep"},{"issue":"1","key":"4559_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2012.04.009","volume":"61","author":"M Hao","year":"2012","unstructured":"Hao M, Kuang HY, Fu Z, Gao XY, Liu Y, Deng W. Exenatide prevents high-glucose-induced damage of retinal ganglion cells through a mitochondrial mechanism. Neurochem Int. 2012;61(1):1\u20136. https:\/\/doi.org\/10.1016\/j.neuint.2012.04.009.","journal-title":"Neurochem Int"},{"key":"4559_CR44","doi-asserted-by":"publisher","first-page":"175269","DOI":"10.1016\/j.ejphar.2022.175269","volume":"933","author":"YW Chung","year":"2022","unstructured":"Chung YW, Lee JY, Ju HH, Choi JA. Anti-inflammatory effect of glucagon-like peptide-1 receptor agonist on the neurosensory retina in an acute optic nerve injury rat model. Eur J Pharmacol. 2022;933:175269. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175269.","journal-title":"Eur J Pharmacol"},{"key":"4559_CR45","doi-asserted-by":"publisher","unstructured":"Guttenplan KA, Stafford BK, El-Danaf RN, et al. Neurotoxic reactive astrocytes drive neuronal death after retinal injury [published correction appears in cell Rep. 2024 Jun 25; 43(6): 114299. doi: https:\/\/doi.org\/10.1016\/j.Celrep.2024.114299. Cell Rep. 2020;31(12):107776.","DOI":"10.1016\/j.Celrep.2024.114299"},{"key":"4559_CR46","doi-asserted-by":"publisher","first-page":"1156829","DOI":"10.3389\/fncel.2023.1156829","volume":"17","author":"ECN Lawrence","year":"2023","unstructured":"Lawrence ECN, Guo M, Schwartz TD, et al. Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma. Front Cell Neurosci. 2023;17:1156829. https:\/\/doi.org\/10.3389\/fncel.2023.1156829. Published 2023 Jun 9.","journal-title":"Front Cell Neurosci"},{"key":"4559_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.06.003","volume":"51","author":"E Vecino","year":"2016","unstructured":"Vecino E, Rodriguez FD, Ruzafa N, Pereiro X, Sharma SC. Glia-neuron interactions in the mammalian retina. Prog Retin Eye Res. 2016;51:1\u201340. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.06.003.","journal-title":"Prog Retin Eye Res"},{"key":"4559_CR48","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.preteyeres.2023.101169","volume":"93","author":"Y Miao","year":"2023","unstructured":"Miao Y, Zhao GL, Cheng S, Wang Z, Yang XL. Activation of retinal glial cells contributes to the degeneration of ganglion cells in experimental glaucoma. Prog Retin Eye Res. 2023;93:101169. https:\/\/doi.org\/10.1016\/j.preteyeres.2023.101169.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"4559_CR49","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1167\/iovs.09-4727","volume":"52","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Zhang J, Wang Q, et al. Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats. Invest Ophthalmol Vis Sci. 2011;52(1):278\u201385. https:\/\/doi.org\/10.1167\/iovs.09-4727. Published 2011 Jan 5.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"4559_CR50","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00417-008-1004-3","volume":"247","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Wang Q, Zhang J, Lei X, Xu GT, Ye W. Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247(5):699\u2013706. https:\/\/doi.org\/10.1007\/s00417-008-1004-3.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"4559_CR51","doi-asserted-by":"publisher","first-page":"10309","DOI":"10.3390\/ijms241210309","volume":"24","author":"B Mart\u00edn-Carro","year":"2023","unstructured":"Mart\u00edn-Carro B, Donate-Correa J, Fern\u00e1ndez-Villabrille S, et al. Experimental models to study diabetes mellitus and its complications: limitations and new opportunities. Int J Mol Sci. 2023;24(12):10309. https:\/\/doi.org\/10.3390\/ijms241210309. Published 2023 Jun 18.","journal-title":"Int J Mol Sci"},{"key":"4559_CR52","first-page":"1557","volume":"20","author":"Y Fan","year":"2014","unstructured":"Fan Y, Liu K, Wang Q, Ruan Y, Zhang Y, Ye W. Exendin-4 protects retinal cells from early diabetes in Goto-kakizaki rats by increasing the bcl-2\/Bax and bcl-xL\/Bax ratios and reducing reactive gliosis. Mol Vis. 2014;20:1557\u201368. Published 2014 Nov 5.","journal-title":"Mol Vis"},{"issue":"5","key":"4559_CR53","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ajpath.2020.01.011","volume":"190","author":"YW Chung","year":"2020","unstructured":"Chung YW, Lee JH, Lee JY, et al. The anti-inflammatory effects of glucagon-like peptide receptor agonist lixisenatide on the retinal nuclear and nerve fiber layers in an animal Model of early type 2 diabetes. Am J Pathol. 2020;190(5):1080\u201394. https:\/\/doi.org\/10.1016\/j.ajpath.2020.01.011.","journal-title":"Am J Pathol"},{"issue":"6","key":"4559_CR54","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1073\/pnas.74.6.2485","volume":"74","author":"AA Rossini","year":"1977","unstructured":"Rossini AA, Like AA, Chick WL, Appel MC, Cahill GF Jr. Studies of streptozotocin-induced insulitis and diabetes. Proc Natl Acad Sci USA. 1977;74(6):2485\u201389. https:\/\/doi.org\/10.1073\/pnas.74.6.2485.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4251","key":"4559_CR55","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.180605","volume":"193","author":"AA Like","year":"1976","unstructured":"Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science. 1976;193(4251):415\u201317. https:\/\/doi.org\/10.1126\/science.180605.","journal-title":"Science"},{"key":"4559_CR56","doi-asserted-by":"publisher","first-page":"589114","DOI":"10.3389\/fphar.2020.589114","volume":"11","author":"HR Zhou","year":"2021","unstructured":"Zhou HR, Ma XF, Lin WJ, et al. Neuroprotective role of GLP-1 analog for retinal ganglion cells via PINK1\/Parkin-mediated mitophagy in diabetic retinopathy. Front Pharmacol. 2021;11:589114. https:\/\/doi.org\/10.3389\/fphar.2020.589114. Published 2021 Feb 12.","journal-title":"Front Pharmacol"},{"issue":"3","key":"4559_CR57","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s004410050702","volume":"286","author":"T Rauen","year":"1996","unstructured":"Rauen T, Rothstein JD, W\u00e4ssle H. Differential expression of three glutamate transporter subtypes in the rat retina. Cell Tissue Res. 1996;286(3):325\u201336. https:\/\/doi.org\/10.1007\/s004410050702.","journal-title":"Cell Tissue Res"},{"issue":"5","key":"4559_CR58","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/cells14050376","volume":"14","author":"H Seo","year":"2025","unstructured":"Seo H, Park SJ, Song M. Diabetic retinopathy (DR): mechanisms, current therapies, and emerging strategies. Cells. 2025;14(5):376. https:\/\/doi.org\/10.3390\/cells14050376. Published 2025 Mar 4.","journal-title":"Cells"},{"issue":"10","key":"4559_CR59","doi-asserted-by":"publisher","first-page":"5456","DOI":"10.3390\/ijms25105456","volume":"25","author":"F Cappellani","year":"2024","unstructured":"Cappellani F, Regillo CD, Haller JA, Gagliano C, Pulido JS. Exploring the associated genetic causes of diabetic retinopathy as a Model of inflammation in retinal diseases. Int J Mol Sci. 2024;25(10):5456. https:\/\/doi.org\/10.3390\/ijms25105456. Published 2024 May 17.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4559_CR60","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13041-025-01224-8","volume":"18","author":"ZA Mouhammad","year":"2025","unstructured":"Mouhammad ZA, Rombaut A, Berm\u00fadez MYG, et al. Systemic semaglutide provides a mild vasoprotective and antineuroinflammatory effect in a rat model of ocular hypertensive glaucoma. Mol Brain. 2025;18(1):54. https:\/\/doi.org\/10.1186\/s13041-025-01224-8. Published 2025 Jul 1.","journal-title":"Mol Brain"},{"issue":"9735","key":"4559_CR61","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(09)62124-3.","journal-title":"Lancet"},{"key":"4559_CR62","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.exer.2014.05.004","volume":"127","author":"Y Fan","year":"2014","unstructured":"Fan Y, Liu K, Wang Q, Ruan Y, Ye W, Zhang Y. Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-kakizaki rats. Exp Eye Res. 2014;127:104\u201316. https:\/\/doi.org\/10.1016\/j.exer.2014.05.004.","journal-title":"Exp Eye Res"},{"key":"4559_CR63","doi-asserted-by":"publisher","first-page":"101264","DOI":"10.1016\/j.preteyeres.2024.101264","volume":"101","author":"E Borrelli","year":"2024","unstructured":"Borrelli E, Bandello F, Boon CJF, et al. Mitochondrial retinopathies and optic neuropathies: the impact of retinal imaging on modern understanding of pathogenesis, diagnosis, and management. Prog Retin Eye Res. 2024;101:101264. https:\/\/doi.org\/10.1016\/j.preteyeres.2024.101264.","journal-title":"Prog Retin Eye Res"},{"key":"4559_CR64","doi-asserted-by":"publisher","first-page":"1009599","DOI":"10.3389\/fnins.2022.1009599","volume":"16","author":"JHC Wong","year":"2022","unstructured":"Wong JHC, Ma JYW, Jobling AI, et al. Exploring the pathogenesis of age-related macular degeneration: a review of the interplay between retinal pigment epithelium dysfunction and the innate immune system. Front Neurosci. 2022;16:1009599. https:\/\/doi.org\/10.3389\/fnins.2022.1009599. Published 2022 Nov 3.","journal-title":"Front Neurosci"},{"issue":"10","key":"4559_CR65","doi-asserted-by":"publisher","first-page":"107772","DOI":"10.1016\/j.jbc.2024.107772","volume":"300","author":"DT Hass","year":"2024","unstructured":"Hass DT, Pandey K, Engel A, et al. Acetyl-CoA carboxylase inhibition increases retinal pigment epithelial cell fatty acid flux and restricts apolipoprotein efflux. J Biol Chem. 2024;300(10):107772. https:\/\/doi.org\/10.1016\/j.jbc.2024.107772.","journal-title":"J Biol Chem"},{"issue":"18","key":"4559_CR66","doi-asserted-by":"publisher","first-page":"9341","DOI":"10.18632\/aging.204647","volume":"15","author":"F Li","year":"2023","unstructured":"Li F, Lei C, Gong K, Bai S, Sun L. Palmitic acid promotes human retinal pigment epithelial cells migration by upregulating miR-222 expression and inhibiting numb. Aging (Albany NY). 2023;15(18):9341\u201357. https:\/\/doi.org\/10.18632\/aging.204647.","journal-title":"Aging (albany NY)"},{"issue":"8","key":"4559_CR67","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.3390\/ijms26083704","volume":"26","author":"SH Tsou","year":"2025","unstructured":"Tsou SH, Luo KS, Huang CN, et al. Liraglutide attenuates FFA-Induced retinal pigment epithelium dysfunction via AMPK activation and lipid homeostasis regulation in ARPE-19 cells. Int J Mol Sci. 2025;26(8):3704. https:\/\/doi.org\/10.3390\/ijms26083704. Published 2025 Apr 14.","journal-title":"Int J Mol Sci"},{"key":"4559_CR68","doi-asserted-by":"publisher","first-page":"117914","DOI":"10.1016\/j.lfs.2020.117914","volume":"256","author":"S Pal","year":"2020","unstructured":"Pal S, Rao GN, Pal A. High glucose-induced ROS accumulation is a critical regulator of ERK1\/2-Akt-tuberin-mTOR signalling in RGC-5 cells. Life Sci. 2020;256:117914. https:\/\/doi.org\/10.1016\/j.lfs.2020.117914.","journal-title":"Life Sci"},{"issue":"1","key":"4559_CR69","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5114\/ceji.2022.115710","volume":"47","author":"J Pan","year":"2022","unstructured":"Pan J, Liu H, Wu Q, Zhou M. Scopoletin protects retinal ganglion cells 5 from high glucose-induced injury in a cellular model of diabetic retinopathy via ROS-dependent p38 and JNK signaling cascade. Cent Eur J Immunol. 2022;47(1):20\u201329. https:\/\/doi.org\/10.5114\/ceji.2022.115710.","journal-title":"Cent Eur J Immunol"},{"issue":"1","key":"4559_CR70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/15548627.2021.1888244","volume":"18","author":"P Tere\u0161ak","year":"2022","unstructured":"Tere\u0161ak P, Lapao A, Subic N, Boya P, Elazar Z, Simonsen A. Regulation of PRKN-independent mitophagy. Autophagy. 2022;18(1):24\u201339. https:\/\/doi.org\/10.1080\/15548627.2021.1888244.","journal-title":"Autophagy"},{"issue":"4","key":"4559_CR71","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.neures.2006.04.008","volume":"55","author":"T Iwai","year":"2006","unstructured":"Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res. 2006;55(4):352\u201360. https:\/\/doi.org\/10.1016\/j.neures.2006.04.008.","journal-title":"Neurosci Res"},{"issue":"1","key":"4559_CR72","doi-asserted-by":"publisher","first-page":"T31","DOI":"10.1530\/JOE-13-0221","volume":"221","author":"C H\u00f6lscher","year":"2014","unstructured":"H\u00f6lscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol. 2014;221(1):T31\u201341. https:\/\/doi.org\/10.1530\/JOE-13-0221. Published 2014 Mar 7.","journal-title":"J Endocrinol"},{"issue":"17","key":"4559_CR73","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","volume":"31","author":"PL McClean","year":"2011","unstructured":"McClean PL, Parthsarathy V, Faivre E, H\u00f6lscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J Neurosci. 2011;31(17):6587\u201394. https:\/\/doi.org\/10.1523\/JNEUROSCI.0529-11.2011.","journal-title":"J Neurosci"},{"issue":"6","key":"4559_CR74","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s43587-025-00869-3","volume":"5","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen H, Feng Y, et al. Activation of AMPK by GLP-1R agonists mitigates alzheimer-related phenotypes in transgenic mice. Nat Aging. 2025;5(6):1097\u2013113. https:\/\/doi.org\/10.1038\/s43587-025-00869-3.","journal-title":"Nat Aging"},{"issue":"4","key":"4559_CR75","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ajpath.2024.12.003","volume":"195","author":"Y Sun","year":"2025","unstructured":"Sun Y, Zhang Y, Shi F, et al. Characterization and role of glucagon-like peptide 1 receptor in the lacrimal gland: novel insights into diabetic Dry eye pathogenesis. Am J Pathol. 2025;195(4):797\u2013810. https:\/\/doi.org\/10.1016\/j.ajpath.2024.12.003.","journal-title":"Am J Pathol"},{"issue":"3","key":"4559_CR76","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1080\/21655979.2022.2031418","volume":"13","author":"Y Hao","year":"2022","unstructured":"Hao Y, Wei M, Zhang N, Zhang X. Novel glucagon-like peptide-1 analogue exhibits potency-driven G-protein biased agonism with promising effects on diabetes and diabetic dry eye syndrome. Bioengineered. 2022;13(3):5467\u201379. https:\/\/doi.org\/10.1080\/21655979.2022.2031418.","journal-title":"Bioengineered"},{"key":"4559_CR77","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. https:\/\/doi.org\/10.1016\/j.diabres.2019.107843.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"4559_CR78","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12916-023-02753-6","volume":"21","author":"D Zheng","year":"2023","unstructured":"Zheng D, Li N, Hou R, et al. Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies. BMC Med. 2023;21(1):40. https:\/\/doi.org\/10.1186\/s12916-023-02753-6. Published 2023 Feb 3.","journal-title":"BMC Med"},{"issue":"3","key":"4559_CR79","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.diabres.2013.12.041","volume":"103","author":"L Varadhan","year":"2014","unstructured":"Varadhan L, Humphreys T, Walker AB, Varughese GI. The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy. Diabetes Res Clin Pract. 2014;103(3):e37\u201339. https:\/\/doi.org\/10.1016\/j.diabres.2013.12.041.","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"4559_CR80","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00125-024-06132-5","volume":"67","author":"A Eleftheriadou","year":"2024","unstructured":"Eleftheriadou A, Riley D, Zhao SS, et al. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Diabetologia. 2024;67(7):1271\u201382. https:\/\/doi.org\/10.1007\/s00125-024-06132-5.","journal-title":"Diabetologia"},{"issue":"6","key":"4559_CR81","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","volume":"68","author":"I Kapoor","year":"2023","unstructured":"Kapoor I, Sarvepalli SM, D\u2019Alessio D, Grewal DS, Hadziahmetovic M. GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials. Surv Ophthalmol. 2023;68(6):1071\u201383. https:\/\/doi.org\/10.1016\/j.survophthal.2023.07.002.","journal-title":"Surv Ophthalmol"},{"issue":"19","key":"4559_CR82","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"7","key":"4559_CR83","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/archopht.116.7.874","volume":"116","author":"Early worsening of diabetic","year":"1998","unstructured":"Early worsening of diabetic. Retinopathy in the diabetes control and complications trial [published correction appears in arch ophthalmol 1998 Nov; 116(11): 1469]. Arch Ophthalmol. 1998;116(7):874\u201386. https:\/\/doi.org\/10.1001\/archopht.116.7.874.","journal-title":"Arch Ophthalmol"},{"issue":"6471","key":"4559_CR84","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/bmj.290.6471.811","volume":"290","author":"K Dahl-J\u00f8rgensen","year":"1985","unstructured":"Dahl-J\u00f8rgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed). 1985;290(6471):811\u201315. https:\/\/doi.org\/10.1136\/bmj.290.6471.811.","journal-title":"Br Med J (clin Res Ed)"},{"issue":"5","key":"4559_CR85","doi-asserted-by":"publisher","first-page":"108472","DOI":"10.1016\/j.jdiacomp.2023.108472","volume":"37","author":"S Gullaksen","year":"2023","unstructured":"Gullaksen S, Vernstr\u00f8m L, S\u00f8rensen SS, et al. Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: a prespecified secondary analysis of a randomised clinical trial. J Diabetes Complications. 2023;37(5):108472. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108472.","journal-title":"J Diabetes Complications"},{"issue":"1","key":"4559_CR86","doi-asserted-by":"publisher","first-page":"102696","DOI":"10.1016\/j.dsx.2022.102696","volume":"17","author":"SG Albert","year":"2023","unstructured":"Albert SG, Wood EM, Ahir V. Glucagon-like peptide 1-receptor agonists and A1c: good for the heart but less so for the eyes? Diabetes Metab Syndr. 2023;17(1):102696. https:\/\/doi.org\/10.1016\/j.dsx.2022.102696.","journal-title":"Diabetes Metab Syndr"},{"issue":"9","key":"4559_CR87","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/0026-0495(75)90102-x","volume":"24","author":"EM Kohner","year":"1975","unstructured":"Kohner EM, Oakley NW. Diabetic retinopathy. Metabolism. 1975;24(9):1085\u2013102. https:\/\/doi.org\/10.1016\/0026-0495(75)90102-x.","journal-title":"Metabolism"},{"key":"4559_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2019.04.001","volume":"70","author":"E Stef\u00e1nsson","year":"2019","unstructured":"Stef\u00e1nsson E, Olafsdottir OB, Eliasdottir TS, et al. Retinal oximetry: metabolic imaging for diseases of the retina and brain. Prog Retin Eye Res. 2019;70:1\u201322. https:\/\/doi.org\/10.1016\/j.preteyeres.2019.04.001.","journal-title":"Prog Retin Eye Res"},{"issue":"10","key":"4559_CR89","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11892-017-0909-9","volume":"17","author":"T Bek","year":"2017","unstructured":"Bek T. Diameter changes of retinal vessels in diabetic retinopathy. Curr Diab Rep. 2017;17(10):82. https:\/\/doi.org\/10.1007\/s11892-017-0909-9. Published 2017 Aug 8.","journal-title":"Curr Diab Rep"},{"issue":"1","key":"4559_CR90","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/bjo.54.1.11","volume":"54","author":"E Taylor","year":"1970","unstructured":"Taylor E, Dobree JH. Proliferative diabetic retinopathy. Site and size of initial lesions. Br J Ophthalmol. 1970;54(1):11\u201318. https:\/\/doi.org\/10.1136\/bjo.54.1.11.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"4559_CR91","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/bjophthalmol-2016-308894","volume":"101","author":"CM J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen CM, Bek T. Lack of differences in the regional variation of oxygen saturation in larger retinal vessels in diabetic maculopathy and proliferative diabetic retinopathy. Br J Ophthalmol. 2017;101(6):752\u201357. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308894.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"4559_CR92","doi-asserted-by":"publisher","first-page":"100547","DOI":"10.1016\/j.xops.2024.100547","volume":"4","author":"JH Joo","year":"2024","unstructured":"Joo JH, Sharma N, Shaia J, et al. The effect of glucagon-like peptide-1 receptor agonists on diabetic retinopathy at a tertiary care center. Ophthalmol Sci. 2024;4(6):100547. https:\/\/doi.org\/10.1016\/j.xops.2024.100547. Published 2024 May 6.","journal-title":"Ophthalmol Sci"},{"issue":"11","key":"4559_CR93","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.2337\/dc17-2280","volume":"41","author":"A Douros","year":"2018","unstructured":"Douros A, Filion KB, Yin H, et al. Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy. Diabetes Care. 2018;41(11):2330\u201338. https:\/\/doi.org\/10.2337\/dc17-2280.","journal-title":"Diabetes Care"},{"issue":"8","key":"4559_CR94","doi-asserted-by":"publisher","first-page":"103099","DOI":"10.1016\/j.dsx.2024.103099","volume":"18","author":"FS Yen","year":"2024","unstructured":"Yen FS, Wei JC, Shih YH, et al. Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: a propensity based cohort study. Diabetes Metab Syndr. 2024;18(8):103099. https:\/\/doi.org\/10.1016\/j.dsx.2024.103099.","journal-title":"Diabetes Metab Syndr"},{"key":"4559_CR95","doi-asserted-by":"publisher","first-page":"1303238","DOI":"10.3389\/fendo.2023.1303238","volume":"14","author":"L Tan","year":"2024","unstructured":"Tan L, Wang Z, Okoth K, et al. Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis. Front Endocrinol (Lausanne). 2024;14:1303238. https:\/\/doi.org\/10.3389\/fendo.2023.1303238. Published 2024 Jan 3.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4559_CR96","unstructured":"Novo Nordisk A\/S. A research study to look at How Semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS). Clinicaltrials.Gov identifier NCT03811561. Updated April 29, 2025. https:\/\/clinicaltrials.gov\/study\/NCT03811561. Accessed June 4 2025."},{"issue":"4","key":"4559_CR97","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/bph.15683","volume":"179","author":"QN Cui","year":"2022","unstructured":"Cui QN, Stein LM, Fortin SM, Hayes MR. The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma. Br J Pharmacol. 2022;179(4):715\u201326. https:\/\/doi.org\/10.1111\/bph.15683.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"4559_CR98","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.preteyeres.2009.06.001","volume":"28","author":"H Xu","year":"2009","unstructured":"Xu H, Chen M, Forrester JV. Para-inflammation in the aging retina. Prog Retin Eye Res. 2009;28(5):348\u201368. https:\/\/doi.org\/10.1016\/j.preteyeres.2009.06.001.","journal-title":"Prog Retin Eye Res"},{"issue":"11","key":"4559_CR99","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1167\/iovs.09-5103","volume":"51","author":"M Chen","year":"2010","unstructured":"Chen M, Muckersie E, Forrester JV, Xu H. Immune activation in retinal aging: a gene expression study. Invest Ophthalmol Vis Sci. 2010;51(11):5888\u201396. https:\/\/doi.org\/10.1167\/iovs.09-5103.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4559_CR100","doi-asserted-by":"publisher","first-page":"100916","DOI":"10.1016\/j.preteyeres.2020.100916","volume":"83","author":"C Baudouin","year":"2021","unstructured":"Baudouin C, Kolko M, Melik-Parsadaniantz S, Messmer EM. Inflammation in Glaucoma: from the back to the front of the eye, and beyond. Prog Retin Eye Res. 2021;83:100916. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100916.","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"4559_CR101","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ogla.2024.03.005","volume":"7","author":"C Johnson","year":"2024","unstructured":"Johnson C, Pasquale LR, Wirostko B. Glucagon-like peptide 1 receptor agonists: a role in Glaucoma? Ophthalmol Glaucoma. 2024;7(5):419\u201321. https:\/\/doi.org\/10.1016\/j.ogla.2024.03.005.","journal-title":"Ophthalmol Glaucoma"},{"issue":"8","key":"4559_CR102","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ophtha.2025.02.011","volume":"132","author":"P Vasu","year":"2025","unstructured":"Vasu P, Dorairaj EA, Weinreb RN, Huang AS, Dorairaj SK. Risk of glaucoma in patients without diabetes using a glucagon-like peptide 1 receptor agonist. Ophthalmology. 2025;132(8):859\u201368. https:\/\/doi.org\/10.1016\/j.ophtha.2025.02.011.","journal-title":"Ophthalmology"},{"key":"4559_CR103","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ajo.2024.08.030","volume":"269","author":"S Hallaj","year":"2025","unstructured":"Hallaj S, Halfpenny W, Chuter BG, Weinreb RN, Baxter SL, Cui QN. Association between glucagon-like peptide-1 receptor agonists exposure and intraocular pressure change: GLP-1 receptor agonists and intraocular pressure change. Am J Ophthalmol. 2025;269:255\u201365. https:\/\/doi.org\/10.1016\/j.ajo.2024.08.030.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"4559_CR104","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ophtha.2024.03.004","volume":"131","author":"S Niazi","year":"2024","unstructured":"Niazi S, Gnesin F, Thein AS, et al. Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes. Ophthalmology. 2024;131(9):1056\u201363. https:\/\/doi.org\/10.1016\/j.ophtha.2024.03.004.","journal-title":"Ophthalmology"},{"issue":"3","key":"4559_CR105","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ophtha.2024.08.023","volume":"132","author":"J Muayad","year":"2025","unstructured":"Muayad J, Loya A, Hussain ZS, et al. Comparative effects of glucagon-like peptide 1 receptor agonists and metformin on glaucoma risk in patients with type 2 diabetes. Ophthalmology. 2025;132(3):271\u201379. https:\/\/doi.org\/10.1016\/j.ophtha.2024.08.023.","journal-title":"Ophthalmology"},{"issue":"2","key":"4559_CR106","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","volume":"107","author":"J Sterling","year":"2023","unstructured":"Sterling J, Hua P, Dunaief JL, Cui QN, VanderBeek BL. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma. Br J Ophthalmol. 2023;107(2):215\u201320. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319232.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"4559_CR107","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7150\/ijms.90273","volume":"21","author":"CC Chuang","year":"2024","unstructured":"Chuang CC, Wang K, Chang CK, et al. Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus. Int J Med Sci. 2024;21(3):540\u201346. https:\/\/doi.org\/10.7150\/ijms.90273. Published 2024 Jan 12.","journal-title":"Int J Med Sci"},{"key":"4559_CR108","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ajo.2024.12.024","volume":"271","author":"DC Amaral","year":"2025","unstructured":"Amaral DC, Guedes J, Cruz MRB, et al. GLP-1 receptor agonists use and incidence of glaucoma: a systematic review and Meta-analysis. Am J Ophthalmol. 2025;271:488\u201397. https:\/\/doi.org\/10.1016\/j.ajo.2024.12.024.","journal-title":"Am J Ophthalmol"},{"key":"4559_CR109","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/CIA.S463297","volume":"19","author":"C Li","year":"2024","unstructured":"Li C, Zhou L, Sun H, Yang MM. Age-related macular degeneration: a disease of cellular senescence and dysregulated immune homeostasis. Clin Interv Aging. 2024;19:939\u201351. https:\/\/doi.org\/10.2147\/CIA.S463297. Published 2024 May 23.","journal-title":"Clin Interv Aging"},{"issue":"10386","key":"4559_CR110","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","volume":"401","author":"RH Guymer","year":"2023","unstructured":"Guymer RH, Campbell TG. Age-related macular degeneration. Lancet. 2023;401(10386):1459\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(22)02609-5.","journal-title":"Lancet"},{"issue":"7","key":"4559_CR111","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ophtha.2025.01.016","volume":"132","author":"KC Allan","year":"2025","unstructured":"Allan KC, Joo JH, Kim S, et al. Glucagon-like peptide-1 receptor agonist impact on chronic ocular disease including age-related macular degeneration. Ophthalmology. 2025;132(7):748\u201357. https:\/\/doi.org\/10.1016\/j.ophtha.2025.01.016.","journal-title":"Ophthalmology"},{"issue":"7","key":"4559_CR112","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/jamaophthalmol.2025.1455","volume":"143","author":"R Shor","year":"2025","unstructured":"Shor R, Mihalache A, Noori A, et al. Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration. JAMA Ophthalmol. 2025;143(7):587\u201394. https:\/\/doi.org\/10.1001\/jamaophthalmol.2025.1455.","journal-title":"JAMA Ophthalmol"},{"issue":"25","key":"4559_CR113","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1056\/NEJMra1413352","volume":"372","author":"V Biousse","year":"2015","unstructured":"Biousse V, Newman NJ. Ischemic optic neuropathies. N Engl J Med. 2015;372(25):2428\u201336. https:\/\/doi.org\/10.1056\/NEJMra1413352.","journal-title":"N Engl J Med"},{"issue":"8","key":"4559_CR114","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","volume":"142","author":"JT Hathaway","year":"2024","unstructured":"Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732\u201339. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.2296.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"4559_CR115","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaophthalmol.2024.6058","volume":"143","author":"BJ Katz","year":"2025","unstructured":"Katz BJ, Lee MS, Lincoff NS, et al. Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide. JAMA Ophthalmol. 2025;143(3):215\u201320. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.6058.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"4559_CR116","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","volume":"143","author":"CX Cai","year":"2025","unstructured":"Cai CX, Hribar M, Baxter S, et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025;143(4):304\u201314. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.6555.","journal-title":"JAMA Ophthalmol"},{"key":"4559_CR117","doi-asserted-by":"publisher","unstructured":"Lakhani M, Kwan ATH, Mihalache A, et al. Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries. Am J Ophthalmol. https:\/\/doi.org\/10.1016\/j.ajo.2025.05.007. Published online May 16, 2025.","DOI":"10.1016\/j.ajo.2025.05.007"},{"key":"4559_CR118","doi-asserted-by":"publisher","first-page":"106206","DOI":"10.1016\/j.ejps.2022.106206","volume":"175","author":"HB Mohamed","year":"2022","unstructured":"Mohamed HB, Abd El-Hamid BN, Fathalla D, Fouad EA. Current trends in pharmaceutical treatment of dry eye disease: a review. Eur J Pharm Sci. 2022;175:106206. https:\/\/doi.org\/10.1016\/j.ejps.2022.106206.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"4559_CR119","doi-asserted-by":"publisher","first-page":"102257","DOI":"10.1016\/j.clae.2024.102257","volume":"47","author":"M Vidal-Rohr","year":"2024","unstructured":"Vidal-Rohr M, Craig JP, Davies LN, Wolffsohn JS. Classification of dry eye disease subtypes. Cont Lens Anterior Eye. 2024;47(5):102257. https:\/\/doi.org\/10.1016\/j.clae.2024.102257.","journal-title":"Cont Lens Anterior Eye"},{"issue":"5","key":"4559_CR120","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jama.2021.19963","volume":"327","author":"FE Hakim","year":"2022","unstructured":"Hakim FE, Farooq AV. Dry eye disease: an update in 2022. JAMA. 2022;327(5):478\u201379. https:\/\/doi.org\/10.1001\/jama.2021.19963.","journal-title":"JAMA"},{"issue":"3","key":"4559_CR121","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ajo.2004.10.022","volume":"139","author":"I Kaiserman","year":"2005","unstructured":"Kaiserman I, Kaiserman N, Nakar S, Vinker S. Dry eye in diabetic patients. Am J Ophthalmol. 2005;139(3):498\u2013503. https:\/\/doi.org\/10.1016\/j.ajo.2004.10.022.","journal-title":"Am J Ophthalmol"},{"key":"4559_CR122","doi-asserted-by":"publisher","first-page":"1079541","DOI":"10.3389\/fendo.2022.1079541","volume":"13","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Yang L, Wang Q, Li Y, Wei C, Xie L. Mechanistic investigations of diabetic ocular surface diseases. Front Endocrinol (Lausanne). 2022;13:1079541. https:\/\/doi.org\/10.3389\/fendo.2022.1079541. Published 2022 Dec 16.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"4559_CR123","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/1040841X.2022.2142090","volume":"49","author":"Q An","year":"2023","unstructured":"An Q, Zou H. Ocular surface microbiota dysbiosis contributes to the high prevalence of dry eye disease in diabetic patients. Crit Rev Microbiol. 2023;49(6):805\u201314. https:\/\/doi.org\/10.1080\/1040841X.2022.2142090.","journal-title":"Crit Rev Microbiol"},{"issue":"12","key":"4559_CR124","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.18240\/ijo.2016.12.06","volume":"9","author":"T Yu","year":"2016","unstructured":"Yu T, Shi WY, Song AP, Gao Y, Dang GF, Ding G. Changes of meibomian glands in patients with type 2 diabetes mellitus. Int J Ophthalmol. 2016;9(12):1740\u201344. https:\/\/doi.org\/10.18240\/ijo.2016.12.06. Published 2016 Dec 18.","journal-title":"Int J Ophthalmol"},{"key":"4559_CR125","doi-asserted-by":"publisher","first-page":"980714","DOI":"10.3389\/fmed.2022.980714","volume":"9","author":"LY Pan","year":"2022","unstructured":"Pan LY, Kuo YK, Chen TH, Sun CC. Dry eye disease in patients with type II diabetes mellitus: a retrospective, population-based cohort study in Taiwan. Front Med (Lausanne). 2022;9:980714. https:\/\/doi.org\/10.3389\/fmed.2022.980714. Published 2022 Aug 23.","journal-title":"Front Med (Lausanne)"},{"issue":"20","key":"4559_CR126","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.3390\/healthcare11202749","volume":"11","author":"YC Fan","year":"2023","unstructured":"Fan YC, Peng SY, Chang CK, et al. The utilization of glucagon-like peptide 1 agonists and risk of following external eye diseases in type 2 diabetes mellitus individuals: a population-based study. Healthcare (basel). 2023;11(20):2749. https:\/\/doi.org\/10.3390\/healthcare11202749. Published 2023 Oct 17.","journal-title":"Healthcare (basel)"},{"issue":"9","key":"4559_CR127","doi-asserted-by":"publisher","first-page":"e2232584","DOI":"10.1001\/jamanetworkopen.2022.32584","volume":"5","author":"YC Su","year":"2022","unstructured":"Su YC, Hung JH, Chang KC, et al. Comparison of sodium-glucose cotransporter 2 inhibitors vs glucagonlike peptide-1 receptor agonists and incidence of dry eye disease in patients with type 2 diabetes in Taiwan. JAMA Netw Open. 2022;5(9):e2232584. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.32584. Published 2022 Sep 1.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"4559_CR128","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1517\/17425247.2011.628983","volume":"8","author":"K Hosoya","year":"2011","unstructured":"Hosoya K, Tomi M, Tachikawa M. Strategies for therapy of retinal diseases using systemic drug delivery: relevance of transporters at the blood-retinal barrier. Expert Opin Drug Deliv. 2011;8(12):1571\u201387. https:\/\/doi.org\/10.1517\/17425247.2011.628983.","journal-title":"Expert Opin Drug Deliv"},{"key":"4559_CR129","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.addr.2018.07.009","volume":"130","author":"M Yu","year":"2018","unstructured":"Yu M, Benjamin MM, Srinivasan S, et al. Battle of GLP-1 delivery technologies. Adv Drug Deliv Rev. 2018;130:113\u201330. https:\/\/doi.org\/10.1016\/j.addr.2018.07.009.","journal-title":"Adv Drug Deliv Rev"},{"key":"4559_CR130","doi-asserted-by":"publisher","first-page":"1055087","DOI":"10.3389\/fimmu.2022.1055087","volume":"13","author":"T Yue","year":"2022","unstructured":"Yue T, Shi Y, Luo S, Weng J, Wu Y, Zheng X. The role of inflammation in immune system of diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Front Immunol. 2022;13:1055087. https:\/\/doi.org\/10.3389\/fimmu.2022.1055087. Published 2022 Dec 13.","journal-title":"Front Immunol"},{"key":"4559_CR131","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.biopha.2018.10.185","volume":"109","author":"A Julius","year":"2019","unstructured":"Julius A, Hopper W. A non-invasive, multi-target approach to treat diabetic retinopathy. Biomed Pharmacother. 2019;109:708\u201315. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.185.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"4559_CR132","doi-asserted-by":"publisher","first-page":"167758","DOI":"10.1016\/j.bbadis.2025.167758","volume":"1871","author":"H Zhu","year":"2025","unstructured":"Zhu H, Li B, Huang T, et al. Update in the molecular mechanism and biomarkers of diabetic retinopathy. Biochim Biophys Acta Mol Basis Dis. 2025;1871(5):167758. https:\/\/doi.org\/10.1016\/j.bbadis.2025.167758.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"4559_CR133","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12951-024-02330-w","volume":"22","author":"X Wang","year":"2024","unstructured":"Wang X, Xu C, Bian C, et al. M2 microglia-derived exosomes promote vascular remodeling in diabetic retinopathy. J Nanobiotechnol. 2024;22(1):56. https:\/\/doi.org\/10.1186\/s12951-024-02330-w. Published 2024 Feb 9.","journal-title":"J Nanobiotechnol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04559-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04559-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04559-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:16:45Z","timestamp":1781626605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-025-04559-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":133,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4559"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04559-x","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}